Holen Sie sich die Stockscreener-App
34.10
0.41%
0.14
Schlusskurs vom Vortag:
$33.96
Offen:
$33.38
24-Stunden-Volumen:
885.09K
Relative Volume:
0.40
Marktkapitalisierung:
$3.80B
Einnahmen:
$-665.00K
Nettoeinkommen (Verlust:
$-150.11M
KGV:
-22.63
EPS:
-1.5071
Netto-Cashflow:
$-124.53M
1W Leistung:
-1.84%
1M Leistung:
+55.92%
6M Leistung:
+126.58%
1J Leistung:
+242.71%
1-Tages-Spanne:
$33.38
$34.24
1-Wochen-Bereich:
$32.98
$35.48
52-Wochen-Spanne:
$9.75
$41.14
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Telefon
617-682-0917
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
34.10 | 4.42B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-03 | Eingeleitet | Stifel | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - Yahoo Finance
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company? - Yahoo Finance
MercadoLibre Stock And 2 High Growth Picks With Strong Balance Sheets - Sahm
Amylyx Pharmaceuticals (AMLX) co-CEO nets 60K performance shares - Stock Titan
Amylyx (NASDAQ: AMLX) CMO’s stock award lifts stake to 288,092 shares - Stock Titan
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide - TipRanks
Amylyx Pharmaceuticals Announces $471.7 Million Public Stock Offering Priced at $35.50 Per Share - Kalkine Media
Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M - TradingView
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Jumps to Fresh Three-Year High as Avexitide Phase 3 Results Bolster Commercial Path - Vinanet
HC Wainwright Has Strong Forecast for AMLX FY2028 Earnings - MarketBeat
39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP - MarketBeat
Amylyx prices $500M stock offering at $35.50 per share - Investing.com
Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock - TradingView
Guggenheim raises Amylyx stock price target on trial results By Investing.com - Investing.com Australia
Amylyx (AMLX) Q2 2026 Earnings Call Transcript - AOL.com
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win - The Globe and Mail
AMYLYX PHARMACEUTICALS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $40 FROM $28 - Bitget
Amylyx successful phase 3 trials for blood sugar drug - EMJ
AMYLYX PHARMACEUTICALS, INC. : MIZUHO RAISES TARGET PRICE TO $42 FROM $30 - Bitget
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Guggenheim Boosts Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $55.00 - MarketBeat
A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $32 to $55 - Moomoo
Guggenheim raises Amylyx stock price target on trial results - Investing.com
Amylyx Stock Sinks As Big Share Sale Spooks Wall Street - TipRanks
Robert W. Baird Forecasts Strong Price Appreciation for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Amylyx’s $35m-acquired PBH drug meets endpoints in Phase III trial - Yahoo
Mizuho Adjusts PT on Amylyx Pharmaceuticals to $42 From $30, Maintains Outperform Rating - Moomoo
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Wolfe Research - MarketBeat
Amylyx Pharmaceuticals (AMLX) Posts Phase 3 Avexitide Win And Follows With Equity Raise - Yahoo Finance
Jason Gerberry Boosts Amylyx Price Target to $39 on Strong LUCIDITY Phase 3 Avexitide Data and $1.8B Peak Sales Outlook - TipRanks
Why Flexsteel Industries Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Sahm
Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level - sahmcapital.com
Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial - KWSN
Amylyx moves to raise USD 350m after avexitide's Phase III hypoglycemia win - AllSci
Amylyx Pharmaceuticals (AMLX) Is Up 48.6% After Positive Phase 3 Avexitide Data And $350M Equity RaiseHas The Bull Case Changed? - simplywall.st
Amylyx Just Printed a Phase 3 Win Wall Street Wasn't Pricing - Money Morning
Key facts: Amylyx (AMLX) Files $350M Offering; Target Raised to $55 - TradingView
Amylyx Avexitide Meets Primary Endpoint in Phase 3 Post-Bariatric Hypoglycemia Trial - The Clinical Trial Vanguard
AMYLYX PHARMACEUTICALS, INC. : BAIRD RAISES TARGET PRICE TO $52 FROM $28 - Bitget
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock - BioSpace
Under the Radar: Amylyx Stock Surges On Positive Trial Results -- WSJ - moomoo.com
Amylyx Announces Positive Phase 3 Data for Avexitide, Shares Surge - NAI500
Amylyx Pharmaceuticals, Inc. stock Analysis: August 2026 Surge & Outlook - The Cryptonomist
Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? - TradingView
Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' R - Benzinga
Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today - TradingView
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amylyx Pharmaceuticals Inc-Aktie (AMLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer |
Jul 10 '26 |
Sale |
17.61 |
15,000 |
264,122 |
179,090 |
1.66%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):